HMG CoA reductase inhibitors (statins): Do they have a role in age-related macular degeneration?

Survey of Ophthalmology

Volumn 50, Issue 2, 2005, Pages 194-206

  Guymer, Robyn Heather ^a   Chiu, Anthony Wai Ip ^a   Lim, Lyndell ^a   Baird, Paul Nigel ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Age related macular degeneration; HMG CoA; Prophylactic treatment; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; BILE ACID SEQUESTRANT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NICOTINIC ACID; OMEGA 3 FATTY ACID; SIMVASTATIN; TRIAMCINOLONE;

AGING; BLINDNESS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEVELOPED COUNTRY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DYSLIPIDEMIA; GENETICS; HUMAN; NONHUMAN; PATHOGENESIS; PLEIOTROPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR; SUBRETINAL NEOVASCULARIZATION; VISION;

EID: 14844316645     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2004.12.002     Document Type: Review

References (190)

1. -: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
2. -: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 Arch Ophthalmol 119 2001 1417 1436
3. -: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Arch Ophthalmol 117 1999 1329 1345
4. -: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N Engl J Med 339 1998 1349 1357
5. -: Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group Arch Ophthalmol 115 1997 741 747
6. -: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
7. -: Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group Arch Ophthalmol 110 1992 1701 1708
8. -: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group N Engl J Med 330 1994 1029 1035
9. J.H. Abalain, J.L. Carre, and D. Leglise Is age-related macular degeneration associated with serum lipoprotein and lipoparticle levels? Clin Chim Acta 326 2000 97 104
10. A. Abdelsalam, L. Del Priore, and M.A. Zarbin Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression Surv Ophthalmol 44 1999 1 29
11. H. Akiyama, S. Barger, and S. Barnum Inflammation and Alzheimer's disease Neurobiol Aging 21 2000 383 421
12. M.A. Albert, E. Danielson, and N. Rifai Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
13. M. Alvarez de Sotomayor, and R. Andriantsitohaina Simvastatin and Ca(2+) signaling in endothelial cells: involvement of rho protein Biochem Biophys Res Commun 280 2001 486 490
14. P. Baird, E. Guida, and D.T. Chu The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration Invest Ophthalmol Vis Sci 45 2004 1311 1315
15. P.N. Baird, D. Chu, and E. Guida Association of the M55L and Q192R paraoxonase gene polymorphisms with age-related macular degeneration Am J Ophthalmol 138 2004 665 666
16. P.N. Baird, E. Guida, and M. Cain Association studies of the apoprotein (apoE) gene and age related macular degeneration (AMD) Clin Exp Ophthalmol 30 Suppl 2002 275
17. J.I. Belda Sanchís, A. Quijada González, and G. Muñoz Ruiz [Are blood lipids a risk factor for age-related macular degeneration?] Arch Soc Esp Oftalmol 76 2001 13 17
18. S. Bellosta, N. Ferri, and F. Bernini Non-lipid-related effects of statins Ann Med 32 2000 164 176
19. A.C. Bird Doyne Lecture. Pathogenesis of retinal pigment epithelial detachment in the elderly; the relevance of Bruch's membrane change Eye 5 Pt 1 1991 1 12
20. A.C. Bird, and J. Marshall Retinal pigment epithelial detachments in the elderly Trans Ophthalmol Soc UK 105 Pt 6 1986 674 682
21. B.T. Blackman What vitamins should I be taking? N Engl J Med 346 2002 1914 1916 author reply 1914-6
22. M.S. Blumenkranz, S.R. Russell, and M.G. Robey Risk factors in age-related maculopathy complicated by choroidal neovascularization Ophthalmology 93 1986 552 558
23. N.M. Bressler Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2 Arch Ophthalmol 119 2001 198 207
24. N.M. Bressler, J.C. Silva, and S.B. Bressler Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration Retina 14 1994 130 142
25. S.B. Bressler, M.G. Maguire, and N.M. Bressler Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group Arch Ophthalmol 108 1990 1442 1447
26. B.G. Brown, X.-Q. Zhao, and A. Chait Simvastatin amd niacin, antioxidant vitamins or the combination for the prevention of coronary artery disease N Engl J Med 345 2001 1583 1592
27. R.P. Burns, and L. Feeney-Burns Clinico-morphologic correlations of drusen of Bruch's membrane Trans Am Ophthalmol Soc 78 1980 206 225
28. G. Chaine, A. Hullo, and J. Sahel Case-control study of the risk factors for age related macular degeneration. France-DMLA Study Group Br J Ophthalmol 82 1998 996 1002
29. J.K. Challa, M.C. Gillies, and P.L. Penfold Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up Aust NZ J Ophthalmol 26 1998 277 281
30. J.C. Chen, F.W. Fitzke, and D. Pauleikhoff Functional loss in age-related Bruch's membrane change with choroidal perfusion defect Invest Ophthalmol Vis Sci 33 1992 334 340
31. F.C. Chu, T. Kuwabara, and D.G. Cogan Ocular manifestations of familial high-density lipoprotein deficiency (Tangier disease) Arch Ophthalmol 97 1979 1926 1928
32. T.A. Ciulla, A. Harris, and L. Kagemann Choroidal perfusion perturbations in non-neovascular age related macular degeneration Br J Ophthalmol 86 2002 209 213
33. J.R. Crouse, R.P. Byington, and C.D. Furberg HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data Atherosclerosis 138 1998 11 24
34. C.A. Curcio, N.E. Medeiros, and C.L. Millican Photoreceptor loss in age-related macular degeneration Invest Ophthalmol Vis Sci 37 1996 1236 1249
35. C.A. Curcio, and C.L. Millican Basal linear deposit and large drusen are specific for early age-related maculopathy Arch Ophthalmol 117 1999 329 339
36. C.A. Curcio, C.L. Millican, and T. Bailey Accumulation of cholesterol with age in human Bruch's membrane Invest Ophthalmol Vis Sci 42 2001 265 274
37. C.A. Curcio, C. Owsley, and G.R. Jackson Spare the rods, save the cones in aging and age-related maculopathy Invest Ophthalmol Vis Sci 41 2000 2015 2018
38. R.P. Danis, T.A. Ciulla, and L.M. Pratt Intravitreal triamcinolone acetonide in exudative age-related macular degeneration Retina 20 2000 244 250
39. M.J. Davies Acute coronary thrombosis - the role of plaque disruption and its initiation and prevention Eur Heart J 16 Suppl L 1995 3 7
40. J. Davignon, J.S. Cohn, and L. Mabile Apolipoprotein E and atherosclerosis: insight from animal and human studies Clin Chim Acta 286 1999 115 143
41. J. Davignon, R.E. Gregg, and C.F. Sing Apolipoprotein E polymorphism and atherosclerosis Arteriosclerosis 8 1988 1 21
42. P. De Knijff, A.F. Stalenhoef, and M.J. Mol Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia Atherosclerosis 83 1990 89 97
43. C. Delcourt, F. Michel, and A. Colvez Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study Ophthalmic Epidemiol 8 2001 237 249
44. V. Della Vale, L. Scorolli, and R. Meduri Retinal effects of simvastatin in patients affected by age related macular degeneration Annali di Ottalmologia e Clinica Oculistica 126 2000 89 95
45. W. Dichtl, J. Dulak, and M. Frick HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells Arterioscler Thromb Vasc Biol 23 2003 58 63
46. S. Dithmar, C.A. Curcio, and N.A. Le Ultrastructural changes in Bruch's membrane of apolipoprotein E-deficient mice Invest Ophthalmol Vis Sci 41 2000 2035 2042
47. S. Dithmar, N.A. Sharara, and C.A. Curcio Murine high-fat diet and laser photochemical model of basal deposits in Bruch membrane Arch Ophthalmol 119 2001 1643 1649
48. J.E. Eichner, S.T. Dunn, and G. Perveen Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review Am J Epidemiol 155 2002 487 495
49. J.E. Eichner, L.H. Kuller, and T.J. Orchard Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease Am J Cardiol 71 1993 160 165
50. A. Eisner, M.L. Klein, and J.D. Zilis Visual function and the subsequent development of exudative age-related macular degeneration Invest Ophthalmol Vis Sci 33 1992 3091 3102
51. G. Franceschini Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease Am J Cardiol 88 2001 9N 13N
52. E. Friedman Update of the vascular model of AMD Br J Ophthalmol 88 2004 161 163
53. E. Friedman The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration Am J Ophthalmol 130 2000 658 663
54. E. Friedman, M. Ivry, and E. Ebert Increased scleral rigidity and age-related macular degeneration Ophthalmology 96 1989 104 108
55. E. Friedman, T.R. Smith, and T. Kuwabara Senile choroidal vascular patterns and drusen Arch Ophthalmol 69 1963 220 230
56. J. Gass Pathogenesis of disciform detachment of the neuroepithelium Am J Ophthalmol 63 1967 573 589
57. M.C. Gillies, J.M. Simpson, and W. Luo A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results Arch Ophthalmol 121 2003 667 673
58. C.K. Glass, and J.L. Witztum Atherosclerosis. the road ahead Cell 104 2001 503 516
59. J. Goldberg, G. Flowerdew, and E. Smith Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey Am J Epidemiol 128 1988 700 710
60. A.L. Gould, J.E. Rossouw, and N.C. Santanello Cholesterol reduction yields clinical benefit: impact of statin trials Circulation 97 1998 946 952
61. W.R. Green, and S.N. Key Senile macular degeneration: a histopathologic study Trans Am Ophthalmol Soc 75 1977 180 254
62. Z. Gregor, A.C. Bird, and I.H. Chisholm Senile disciform macular degeneration in the second eye Br J Ophthalmol 61 1977 141 147
63. D.H. Gurne, M.O. Tso, and D.P. Edward Antiretinal antibodies in serum of patients with age-related macular degeneration Ophthalmology 98 1991 602 607
64. R. Guymer, P. Luthert, and A. Bird Changes in Bruch's membrane and related structures with age Prog Retin Eye Res 18 1999 59 90
65. G.S. Hageman, P.J. Luthert, and N.H. Victor Chong An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration Prog Retin Eye Res 20 2001 705 732
66. R. Haimovici, D.L. Gantz, and S. Rumelt The lipid composition of drusen, Bruch's membrane, and sclera by hot stage polarizing light microscopy Invest Ophthalmol Vis Sci 42 2001 1592 1599
67. N.F. Hall, C.R. Gale, and H. Syddall Risk of macular degeneration in users of statins: cross sectional study BMJ 323 2001 375 376
68. C.R. Harper, and T.A. Jacobson The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease Arch Intern Med 161 2001 2185 2192
69. A. Harris, H.S. Chung, and T.A. Ciulla Progress in measurement of ocular blood flow and relevance to our understanding of glaucoma and age-related macular degeneration Prog Retin Eye Res 18 1999 669 687
70. D.C. Hess, and S.C. Fagan Pharmacology and clinical experience with simvastatin Expert Opin Pharmacother 2 2001 153 163
71. R.A. Heuberger, J.A. Mares-Perlman, and R. Klein Relationship of dietary fat to age-related maculopathy in the Third National Health and Nutrition Examination Survey Arch Ophthalmol 119 2001 1833 1838
72. H. Hirvelä, H. Luukinen, and E. Läärä Risk factors of age-related maculopathy in a population 70 years of age or older Ophthalmology 103 1996 871 877
73. F.G. Holz, G. Sheraidah, and D. Pauleikhoff Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane Arch Ophthalmol 112 1994 402 406
74. F.G. Holz, T.J. Wolfensberger, and B. Piguet Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors Ophthalmology 101 1994 1522 1528
75. B. Horejsí, and R. Ceska Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis Physiol Res 49 Suppl 1 2000 S63 S69
76. X. Huang, M.P. Cuajungco, and C.S. Atwood Alzheimer's disease, beta-amyloid protein and zinc J Nutr 130 2000 1488S 1492S
77. D.B. Hunninghake, R.H. Knopp, and G. Schonfeld Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study Atherosclerosis 85 1990 81 89
78. L. Hyman, A.P. Schachat, and Q. He Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group Arch Ophthalmol 118 2000 351 358
79. L.G. Hyman, A.M. Lilienfeld, and F.L. Ferris Senile macular degeneration: a case-control study Am J Epidemiol 118 1983 213 227
80. T. Ikeda, H. Obayashi, and G. Hasegawa Paraoxonase gene polymorphisms and plasma oxidized low-density lipoprotein level as possible risk factors for exudative age-related macular degeneration Am J Ophthalmol 132 2001 191 195
81. I. Inoue, S. Goto, and K. Mizotani Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary e Life Sci 67 2000 863 876
82. T. Ishibashi, H. Miller, and G. Orr Morphologic observations on experimental subretinal neovascularization in the monkey Invest Ophthalmol Vis Sci 28 1987 1116 1130
83. G.R. Jackson, C. Owsley, and E.P. Price Cordle Aging and scotopic sensitivity Vision Res 38 1998 469 477
84. S.G. Jacobson, A.V. Cideciyan, and G. Regunath Night blindness in Sorsby's fundus dystrophy reversed by vitamin A Nat Genet 11 1995 27 32
85. G.P. Jarvik, E.M. Wijsman, and W.A. Kukull Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study Neurology 45 1995 1092 1096
86. I. Jialal, D. Stein, and D. Balis Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels Circulation 103 2001 1933 1935
87. H. Jick, G.L. Zornberg, and S.S. Jick Statins and the risk of dementia Lancet 356 2000 1627 1631
88. J.B. Jonas, I. Kreissig, and P. Hugger Intravitreal triamcinolone acetonide for exudative age related macular degeneration Br J Ophthalmol 87 2003 462 468
89. C.M. Kemp, S.G. Jacobson, and D.J. Faulkner Visual function and rhodopsin levels in humans with vitamin A deficiency Exp Eye Res 46 1988 185 197
90. C.C. Klaver, J.J. Assink, and van Leeuwen Incidence and progression rates of age-related maculopathy the Rotterdam Study Invest Ophthalmol Vis Sci 42 2001 2237 2241
91. C.C. Klaver, M. Kliffen, and C.M. van Duijn Genetic association of apolipoprotein E with age-related macular degeneration Am J Hum Genet 63 1998 200 206
92. B.E. Klein, R. Klein, and K.E. Lee Measures of obesity and age-related eye diseases Ophthalmic Epidemiol 8 2001 251 262
93. R. Klein, and B.E. Klein Do statins prevent age-related macular degeneration? Am J Ophthalmol 137 2004 747 749
94. R. Klein, B.E. Klein, and T. Franke The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study Ophthalmology 100 1993 406 414
95. R. Klein, B.E. Klein, and S.C. Jensen Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study Arch Ophthalmol 119 2001 1354 1359
96. R. Klein, B.E. Klein, and S.E. Moss Relation of smoking to the incidence of age-related maculopathy. The Beaver Dam Eye Study Am J Epidemiol 147 1998 103 110
97. R. Klein, B.E. Klein, and S.C. Tomany Relation of statin use to the 5-year incidence and progression of age-related maculopathy Arch Ophthalmol 121 2003 1151 1155
98. R. Klein, B.E. Klein, and S.C. Tomany Ten-year incidence of age-related maculopathy and smoking and drinking: the Beaver Dam Eye Study Am J Epidemiol 156 2002 589 598
99. M. Kliffen, H.S. Sharma, and C.M. Mooy Increased expression of angiogenic growth factors in age-related maculopathy Br J Ophthalmol 81 1997 154 162
100. D.R. Knighton, T.K. Hunt, and H. Scheuenstuhl Oxygen tension regulates the expression of angiogenesis factor by macrophages Science 221 1983 1283 1285
101. W. Kosnik, L. Winslow, and D. Kline Visual changes in daily life throughout adulthood J Gerontol 43 1988 P63 P70
102. J.T. Kuvin, and R.H. Karas The effects of LDL reduction and HDL augmentation on physiologic and inflammatory markers Curr Opin Cardiol 18 2003 295 300
103. B. Kwak, F. Mulhaupt, and N. Veillard The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells Swiss Med Wkly 131 2001 41 46
104. D.M. Lanchoney, M.G. Maguire, and S.L. Fine A model of the incidence and consequences of choroidal neovascularization secondary to age-related macular degeneration. Comparative effects of current treatment and potential prophylaxis on visual outcomes in high-risk patients Arch Ophthalmol 116 1998 1045 1052
105. U. Laufs, V.L. Fata, and J.K. Liao Inhibition of 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase J Biol Chem 272 1997 31725 31729
106. C.S. Leibrock, T. Reuter, and T.D. Lamb Molecular basis of dark adaptation in rod photoreceptors Eye 12 Pt 3b 1998 511 520
107. J.J. Li, and X.J. Chen Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide Coron Artery Dis 14 2003 329 334
108. P.F. Lopez, B.D. Sippy, and H.M. Lambert Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes Invest Ophthalmol Vis Sci 37 1996 855 868
109. R.W. Mahley Apolipoprotein E: cholesterol transport protein with expanding role in cell biology Science 240 1988 622 630
110. R.W. Mahley, Y. Huang, and S.C. Rall Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes J Lipid Res 40 1999 1933 1949
111. B.A. Maltzman, M.N. Mulvihill, and A. Greenbaum Senile macular degeneration and risk factors: a case-control study Ann Ophthalmol 11 1979 1197 1201
112. C.M. Mangione, P.R. Gutierrez, and G. Lowe Influence of age-related maculopathy on visual functioning and health-related quality of life Am J Ophthalmol 128 1999 45 53
113. J.A. Mares-Perlman, W.E. Brady, and R. Klein Dietary fat and age-related maculopathy Arch Ophthalmol 113 1995 743 748
114. C.A. McCarty, B.N. Mukesh, and C.L. Fu Risk factors for age-related maculopathy: the Visual Impairment Project Arch Ophthalmol 119 2001 1455 1462
115. C.A. McCarty, B.N. Mukesh, and R.H. Guymer Cholesterol-lowering medications reduce the risk of age-related maculopathy progression Med J Aust 175 2001 340
116. G. McGwin, C. Owsley, and C.A. Curcio The association between statin use and age related maculopathy Br J Ophthalmol 87 2003 1121 1125
117. A. Mertens, and P. Holvoet Oxidized LDL and HDL: antagonists in atherothrombosis FASEB J 15 2001 2073 2084
118. P. Mitchell, W. Smith, and K. Attebo Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study Ophthalmology 102 1995 1450 1460
119. P. Mitchell, J.J. Wang, and W. Smith Smoking and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study Arch Ophthalmol 120 2002 1357 1363
120. D.J. Moore, A.A. Hussain, and J. Marshall Age-related variation in the hydraulic conductivity of Bruch's membrane Invest Ophthalmol Vis Sci 36 1995 1290 1297
121. O. Neuhaus, S. Strasser-Fuchs, and F. Fazekas Statins as immunomodulators: comparison with interferon-beta 1b in MS Neurology 59 2002 990 997
122. I.L. Notkola, R. Sulkava, and J. Pekkanen Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease Neuroepidemiology 17 1988 14 20
123. G.S. Omenn, G.E. Goodman, and M.D. Thornquist Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease N Engl J Med 334 1996 1150 1155
124. J.M. Ong, N.C. Zorapapel, and K.A. Rich Effects of cholesterol and apolipoprotein E on retinal abnormalities in ApoE-deficient mice Invest Ophthalmol Vis Sci 42 2001 1891 1900
125. J.A. Oosterhuis The architecture of the choroidal vascular system in clinical ophthalmology Excerpta Med 23 1978 242 248
126. C. Owsley, G.R. Jackson, and A.V. Cideciyan Psychophysical evidence for rod vulnerability in age-related macular degeneration Invest Ophthalmol Vis Sci 41 2000 267 273
127. C. Owsley, G.R. Jackson, and M. White Delays in rod-mediated dark adaptation in early age-related maculopathy Ophthalmology 108 2001 1196 1202
128. D.V. Parums, D.L. Brown, and M.J. Mitchinson Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis Arch Pathol Lab Med 114 1990 383 387
129. D. Pauleikhoff, M.J. Barondes, and D. Minassian Drusen as risk factors in age-related macular disease Am J Ophthalmol 109 1990 38 43
130. D. Pauleikhoff, J.C. Chen, and I.H. Chisholm Choroidal perfusion abnormality with age-related Bruch's membrane change Am J Ophthalmol 109 1990 211 217
131. D. Pauleikhoff, S. Zuels, and G.S. Sheraidah Correlation between biochemical composition and fluorescein binding of deposits in Bruch's membrane Ophthalmology 99 1992 1548 1553
132. T.R. Pedersen, L. Wilhelmsen, and O. Faergeman Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering Am J Cardiol 86 2000 257 262
133. P.L. Penfold, M.C. Madigan, and M.C. Gillies Immunological and aetiological aspects of macular degeneration Prog Retin Eye Res 20 2001 385 414
134. P.L. Penfold, J.M. Provis, and J.H. Furby Autoantibodies to retinal astrocytes associated with age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 228 1990 270 274
135. J.A. Phipps, R.H. Guymer, and A.J. Vingrys Loss of cone function in age-related maculopathy Invest Ophthalmol Vis Sci 44 2003 2277 2283
136. J.J. Plantner, C. Jiang, and A. Smine Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration Exp Eye Res 67 1998 637 645
137. J.K. Plenge, T.L. Hernandez, and K.M. Weil Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction Circulation 106 2002 1447 1452
138. J. Poirier, A. Baccichet, and D. Dea Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats Neuroscience 55 1993 81 90
139. J. Poirier, A. Minnich, and J. Davignon Apolipoprotein E, synaptic plasticity and Alzheimer's disease Ann Med 27 1995 663 670
140. D. Pruefer, R. Scalia, and A.M. Lefer Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats Arterioscler Thromb Vasc Biol 19 1999 2894 2900
141. D.J. Rader, and C. Maugeais Genes influencing HDL metabolism: new perspectives and implications for atherosclerosis prevention Mol Med Today 6 2000 170 175
142. R.S. Ramrattan, T.L. van der Schaft, and C.M. Mooy Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging Invest Ophthalmol Vis Sci 35 1994 2857 2864
143. P.D. Richardson, M.J. Davies, and G.V. Born Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques Lancet 2 1989 941 944
144. P.M. Ridker, C.H. Hennekens, and J.E. Buring C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836 843
145. P.M. Ridker, N. Rifai, and M.A. Pfeffer Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators Circulation 100 1999 230 235
146. R. Ross Atherosclerosis is an inflammatory disease Am Heart J 138 Suppl 1999 419 420
147. L.L. Rulon, J.D. Robertson, and M.A. Lovell Serum zinc levels and Alzheimer's disease Biol Trace Elem Res 75 2000 79 85
148. S.H. Sarks Drusen patterns predisposing to geographic atrophy of the retinal pigment epithelium Aust J Ophthalmol 10 1982 91 97
149. S.H. Sarks Senile choroidal sclerosis Br J Ophthalmol 57 1973 98 109
150. F. Schächter, L. Faure-Delanef, and F. Guénot Genetic associations with human longevity at the APOE and ACE loci Nat Genet 6 1994 29 32
151. D.A. Schaumberg, W.G. Christen, and S.E. Hankinson Body mass index and the incidence of visually significant age-related maculopathy in men Arch Ophthalmol 119 2001 1259 1265
152. A. Scuteri, A.J.G. Bos, and A.B. Zonderman Is the apoE4 allele an independent predictor of coronary events? Am J Med 110 2001 28 32
153. J.M. Seddon, G. Gensler, and R.C. Milton Association between C-reactive protein and age-related macular degeneration JAMA 291 2004 704 710
154. J.M. Seddon, B. Rosner, and R.D. Sperduto Dietary fat and risk for advanced age-related macular degeneration Arch Ophthalmol 119 2001 1191 1199
155. C.J. Segal-Isaacson, and J. Wylie-Rosett The cardiovascular effects of fish oils and omega-3 fatty acids Heart Dis 1 1999 149 154
156. D. Seigel AREDS investigators distort findings Arch Ophthalmol 120 2002 100 101
157. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
158. W. Smith, J. Assink, and R. Klein Risk factors for age-related macular degeneration Pooled findings from three continents Ophthalmology 108 2001 697 704
159. W. Smith, P. Mitchell, and S.R. Leeder Dietary fat and fish intake and age-related maculopathy Arch Ophthalmol 118 2000 401 404
160. W. Smith, P. Mitchell, and S.R. Leeder Smoking and age-related maculopathy. The Blue Mountains Eye Study Arch Ophthalmol 114 1996 1518 1523
161. W. Smith, P. Mitchell, and S.R. Leeder Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study Arch Ophthalmol 116 1998 583 587
162. E.H. Souied, P. Benlian, and P. Amouyel The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration Am J Ophthalmol 125 1998 353 359
163. R.F. Spaide, W.C. Ho-Spaide, and R.W. Browne Characterization of peroxidized lipids in Bruch's membrane Retina 19 1999 141 147
164. R.D. Sperduto, and R. Hiller Systemic hypertension and age-related maculopathy in the Framingham Study Arch Ophthalmol 104 1986 216 219
165. C. Starita, A.A. Hussain, and J. Marshall Decreasing hydraulic conductivity of Bruch's membrane: relevance to photoreceptor survival and lipofuscinoses Am J Med Genet 57 1995 235 237
166. C. Starita, A.A. Hussain, and A. Patmore Localization of the site of major resistance to fluid transport in Bruch's membrane Invest Ophthalmol Vis Sci 38 1997 762 767
167. B. Steen, S. Sejersen, and L. Berglin Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes Invest Ophthalmol Vis Sci 39 1998 2194 2200
168. D. Steinberg, S. Parthasarathy, and T.E. Carew Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity N Engl J Med 320 1989 915 924
169. R.L. Steinmetz, P.C. Polkinghorne, and F.W. Fitzke Abnormal dark adaptation and rhodopsin kinetics in Sorsby's fundus dystrophy Invest Ophthalmol Vis Sci 33 1992 1633 1636
170. W.J. Strittmatter, and A.D. Roses Apolipoprotein E and Alzheimer disease Proc Natl Acad Sci USA 92 1995 4725 4727
171. W.J. Strittmatter, A.M. Saunders, and D. Schmechel Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease Proc Natl Acad Sci USA 90 1993 1977 1981
172. J.S. Sunness, R.W. Massof, and M.A. Johnson Diminished foveal sensitivity may predict the development of advanced age-related macular degeneration Ophthalmology 96 1989 375 381
173. M. Takemoto, and J.K. Liao Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors Arterioscler Thromb Vasc Biol 21 2001 1712 1719
174. M.O. Tso Pathogenetic factors of aging macular degeneration Ophthalmology 92 1985 628 635
175. R. Van Leeuwen, C. Klaver, and J.R. Vingerling Cholesterol and age-related macular degeneration: Is there a link? Am J Ophthalmol 137 2004 750 752
176. R. van Leeuwen, J.R. Vingerling, and P.T. de Jong Risk of macular degeneration with statin use should be interpreted with caution BMJ 323 2001 1308
177. R. van Leeuwen, J.R. Vingerling, and A. Hofman Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement BMJ 326 2003 255 256
178. M.R. VanNewkirk, M.B. Nanjan, and J.J. Wang The prevalence of age-related maculopathy: the visual impairment project Ophthalmology 107 2000 1593 1600
179. C.J. Vaughan, A.M. Gotto, and C.T. Basson The evolving role of statins in the management of atherosclerosis J Am Coll Cardiol 35 2000 1 10
180. J.S. Vidaurri, J. Pe'er, and S.T. Halfon Association between drusen and some of the risk factors for coronary artery disease Ophthalmologica 188 1984 243 247
181. T. Vinding, M. Appleyard, and J. Nyboe Risk factor analysis for atrophic and exudative age-related macular degeneration. An epidemiological study of 1000 aged individuals Acta Ophthalmol (Copenh) 70 1992 66 72
182. J.R. Vingerling, I. Dielemans, and M.L. Bots Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study Am J Epidemiol 142 1995 404 409
183. J.R. Vingerling, A. Hofman, and D.E. Grobbee Age-related macular degeneration and smoking. The Rotterdam Study Arch Ophthalmol 114 1996 1193 1196
184. S. Wassman, A. Faul, and H. Benno Rapid effect of 3-Hydroxy-3- Methylglutaryl Coenzyme A Reductase inhibition on coronary endothelial function Circ Res 93 2003 98 103
185. F. Watts Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities Curr Control Trials Cardiovasc Med 2 2001 118 122
186. H.L. Wilson, D.M. Schwartz, and H.R. Bhatt Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration Am J Ophthalmol 137 2004 615 624
187. G. Wolf The effect of low and high doses of beta-carotene and exposure to cigarette smoke on the lungs of ferrets Nutr Rev 60 2002 88 90
188. B. Wolozin, W. Kellman, and P. Ruosseau Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors Arch Neurol 57 2000 1439 1443
189. X. Yi, N. Ogata, and M. Komada Vascular endothelial growth factor expression in choroidal neovascularization in rats Graefe's Arch Clin Exp Ophthalmol 235 1997 313 319
190. S. Youssef, O. Stüve, and J.C. Patarroyo The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease Nature 420 2002 78 84